cyperenoic-acid and Disease-Models--Animal

cyperenoic-acid has been researched along with Disease-Models--Animal* in 2 studies

Other Studies

2 other study(ies) available for cyperenoic-acid and Disease-Models--Animal

ArticleYear
Cyperenoic acid suppresses osteoclast differentiation and delays bone loss in a senile osteoporosis mouse model by inhibiting non-canonical NF-κB pathway.
    Scientific reports, 2018, 04-04, Volume: 8, Issue:1

    Topics: Animals; Bone Resorption; Cell Differentiation; Cells, Cultured; Disease Models, Animal; Female; Mice; Mice, Inbred BALB C; NF-kappa B; Osteoclasts; Osteoporosis; Sesquiterpenes

2018
Gastroprotective activity and cytotoxic effect of cyperenoic acid derivatives.
    The Journal of pharmacy and pharmacology, 2006, Volume: 58, Issue:11

    The gastroprotective effect of the sesquiterpene cyperenoic acid and seven semi-synthetic derivatives was assessed in the HCl/ethanol-induced gastric ulcer model in mice. At doses of 25, 50 and 100 mg kg(-1), cyperenoic acid showed a dose-dependent gastroprotective effect reducing the lesions by 45 and 75% at 50 and 100 mg kg(-1), respectively. Seven derivatives of the sesquiterpene were prepared and their gastroprotective activity compared at 50 mg kg(-1). The cytotoxicity of the compounds was evaluated in fibroblasts and AGS cells. At 50 mg kg(-1), patchoulan-15-oic acid (compound 8) presented the best gastroprotective effect, reducing the gastric lesions by 86%, with a similar effect to lansoprazole at 20 mg kg(-1). The gastroprotective effect of cyperenol, cyperenoic acid methyl ester and the ethylamide and butylamide from cyperenoic acid were in the same range, reducing the gastric lesions by 72-77%. Cyperenol and cyperenoic acid methyl ester, however, were more cytotoxic with IC50 (concentration that produces a 50% inhibitory effect) values of 44 and 75, 48 and 75 microM against AGS cells and fibroblasts, respectively. The best gastroprotective effect with lower cytotoxicity was found for the compound 8, cyperenoic acid and the p-anisidyl derivative 7.

    Topics: Administration, Oral; Animals; Anti-Ulcer Agents; Cell Line; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Female; Humans; Hydrochloric Acid; Inhibitory Concentration 50; Jatropha; Magnetic Resonance Spectroscopy; Male; Mice; Molecular Structure; Plant Extracts; Rhizome; Sesquiterpenes; Solubility; Stomach Ulcer; Toxicity Tests

2006